Ember Therapeutics to Present at Marcum MicroCap Conference
Tweet
Share
E-mailNEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB: EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.
Details of the presentation are as follows:
| Conference: | 2016 Marcum MicroCap Conference |
| Date: | Wednesday, June 1, 2016 |
| Time: | 4:00 p.m. EDT |
| Location: | Grand Hyatt New York, Broadway Room |
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a clinical stage biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 to catalyze cartilage regeneration for disease modification of Osteoarthritis (OA) and the inhibition and reversal of organ fibrosis in diseases such as Chronic Kidney Disease (CKD) and Alport Syndrome. In particular, Ember has acquired over 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and cGMP manufactured material from Stryker Corporation. For more information, please visit www.embertx.com.
Contact The Ruth Group Lee Roth (investors) (646) 536-7012 [email protected]Source: Ember Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
- Cater to Your Heroes With Perkins Restaurant & Bakery®
- Whirlpool Sustainability Report: Our Value Chain
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
